The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Hildegard Greinix
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
According to a recent study, following the 8-week treatment of patients with steroid-refractory chronic GvHD with ECP alone, which of the following immunological effects does adding low-dose IL-2 to ECP treatment have on patients’ lymphocytes?
A
B
C
D
Video series
On November 29, 2022, the GvHD Hub held a virtual symposium on the role of extracorporeal photopheresis (ECP) in the management of graft-versus-host disease (GvHD).
Here, we share the presentation given by Professor Hildegard Greinix, Medical University of Graz, Graz, AT, which considered ECP and how it works.
In this presentation, Professor Greinix details the process of ECP (Figure 1), as well as its direct and indirect effects at a cellular level, and discusses the use of ECP, alone or in combination, for both chronic and acute GvHD, and its impact on quality of life (Figure 2), referencing data and outcomes from multiple research studies.
Figure 1. The process of ECP*
ECP, extracorporeal photopheresis; GvHD, graft-versus-host disease; UVA, ultraviolet A.
*Adapted from Knobler, et al.1 Created with BioRender.com.
Figure 2. Quality of life during ECP treatment*†
ECP, extracorporeal photopheresis; SF-36, 36-item short form health survey; SoC, standard of care.
*Copyright © 2022 by Elsevier. Reproduced with permission. Jagasia M, et al. Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD Blood Adv. 2019;3(14):2218-2229. DOI: 10.1182/bloodadvances.20190001452
†The SF-36 domains of quality of life were scored from 0 to 100.
Watch or download the presentation to learn more about ECP, including:
- What ECP is and how it works (0:16; slides 5–6)
- The Impacts of ECP (3:00; slides 7–8)
- ECP in acute GvHD (5:17; slides 10–17)
- ECP in chronic GvHD (15:09; slides 19–28)
- Quality of life during treatment (25:33; slides 29–30)
- Combination treatments with ECP (26:32; slides 32–35)
- Approved and recommended uses for ECP (33:56; slides 37–38)
Key points
- ECP is a process in which blood is externally centrifuged and white blood cells are treated with methoxsalen and ultraviolet A light before being returned to the patient.
- ECP causes the depletion of alloreactive donor T cells that can cause GvHD.
- ECP is associated with superior survival compared with anticytokine therapy.
- Treatment with ECP is well tolerated, with no severe cytopenias recorded.
- ECP is approved for the treatment of advanced cutaneous T-cell lymphoma.
- ECP is recommended as a second-line treatment for steroid-refractory acute and chronic GvHD.
This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
More from this series:
